Kye Pharmaceuticals Ranks on Canada's Top Growing Companies List
Kye Pharmaceuticals has secured the No. 105 spot on The Globe and Mail's eighth annual ranking of Canada's Top Growing Companies. The company achieved 264% revenue growth over three years.
Mississauga, ON – Kye Pharmaceuticals has been ranked No. 105 on The Globe and Mail's eighth annual list of Canada's Top Growing Companies. The ranking recognizes Canadian companies based on three-year revenue growth, with Kye Pharmaceuticals achieving 264% growth.
This marks the second consecutive year Kye Pharmaceuticals has been included on the list. John McKendry, President & CEO, stated that the company's growth reflects the team's success and the value its medicines deliver to an increasing number of patients across Canada. The recognition highlights Kye's progress in bringing medicines for high unmet medical needs to the Canadian market.
Canada's Top Growing Companies is an annual editorial ranking that celebrates the achievements of Canadian businesses. Companies qualify through an in-depth application process and by meeting specific revenue growth targets over a three-year period. A total of 376 companies earned a spot on this year's list, which is featured in the October issue of Report on Business magazine.
Kye Pharmaceuticals is a growth-stage specialty pharmaceutical company focused on identifying, licensing, and commercializing novel prescription medicines for the Canadian market. The company's portfolio spans therapeutic areas such as cardiology, psychiatry, pediatrics, rare diseases, hematology, and neurology.